secwatch.observer — SEC 8-K summary
======================================

Issuer:     Embecta Corp. (EMBC)
CIK:        0001872789
Form:       8-K
Filed at:   2025-05-22T23:59:59+00:00
Accession:  0001872789-25-000016
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Embecta reaffirms FY2025 guidance, unveils long-range plan with flat revenue growth, $600M FCF target
--------------------------------------------------------------------------------

- Reaffirmed FY2025 guidance: revenue $1.073-1.090B, adjusted EPS $2.70-$2.90, adjusted gross margin 62.75%-63.75%.
- Long-range plan (2025-2028): flattish constant currency revenue CAGR, adjusted operating margin ~28%-30%.
- Targets ~$600M cumulative free cash flow over LRP; plans to repay $450M-$500M of debt.
- Strategic priorities: strengthen core insulin injection business, expand product portfolio, increase financial flexibility through cost savings and debt reduction.
- Inaugural Analyst and Investor Day held May 22, 2025, with webcast and presentation materials available online.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1872789/000187278925000016/0001872789-25-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1872789/000187278925000016/embc-20250522.htm
  HTML page:      https://secwatch.observer/filing/0001872789-25-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer